Short answer
IRADIMED CORP (IRMD) filed its Q2 2026 10-Q quarterly report on Jul 31, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $20M (up 0.3% year over year) with net income of $5M.
Q2 2026 key financials · XBRL
- Revenue
- $20M
- +0.3% YoY · −6.9% QoQ
- Net income
- $5M
- −9.6% YoY · −10.3% QoQ
- Operating margin
- 31.2%
- Gross margin
- 74.1%
- EPS (diluted)
- $0.41
- −8.9% YoY · −8.9% QoQ
Source: XBRL data from the IRADIMED CORP (IRMD) Q2 2026 10-Q on SEC EDGAR. USD.
IRADIMED CORP Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes in risk factors from the 2025 Annual Report
- Carried-forward business risks remain applicable, including potential unknown or currently immaterial risks becoming material
- No new regulatory, legal, compliance, operational, competitive, market, or financial risk identified this quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other IRADIMED CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.